Gilde Healthcare has invested in Tandarts Today
Gilde Healthcare has invested in Tandarts Today, a fast-growing dental chain in the Netherlands. The investment will allow Tandarts Today to accelerate its buy-and-build strategy and become a leading dental chain in the Netherlands. Financial details have not been disclosed.
Tandarts Today, founded in 2015, offers all disciplines of regular dentistry, including special treatments such as implantology, orthodontics, periodontology and aesthetic treatments. Furthermore, through its own dental laboratories, it develops hockey bits, custom-made prostheses, bridges and other dental work pieces.
Gilde Healthcare is a specialized European healthcare investor managing over US$1.5 billion across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in health tech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies, with a focus on the Benelux and DACH regions. The private equity fund targets healthcare, suppliers of medical products and service providers in the healthcare market.
Oaklins’ team in the Netherlands acted as the exclusive financial advisor to the seller in this transaction.
Ruben Hoefnagels
Founder and CEO, Tandarts Today
Talk to the deal team
Sander van 't Spijker
Senior Associate
Amsterdam, NetherlandsOaklins Netherlands
Related deals
VHZ Group has been acquired by Gilde Equity Management and VHZ Group’s management
VHZ Group, the market leader in the Dutch B2B uPVC windows and doors market, has been acquired by Gilde Equity Management (GEM) together with the company’s management. With the acquisition, VHZ Group and GEM will be able to further expand on the company’s strategy and vision.
Learn moreScreenPoint Medical has raised US$28 million in a Series C investment round led by Insight Partners
Netherlands-based ScreenPoint Medical, an AI technology company that develops advanced image recognition and machine learning software to improve early detection of breast cancer, has raised US$28 million (€24 million) in a Series C funding round led by New York-based global venture capital and private equity firm Insight Partners to further develop its technology and accelerate commercial growth of the company’s Transpara AI breast care software.
Learn moreesignatur has been acquired by Scrive
esignatur has been acquired by Scrive, a portfolio company of Vitruvian Partners. esignatur and Scrive both specialize in digital signing solutions and complement each other with strong geographical and sector reach.
Learn more